Mark Schoenberg - 26 Jan 2022 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Medical Officer
Signature: /s/ Jason Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 26 Jan 2022
Net transactions value: -$898
Form type: 4
Filing time: 28 Jan 2022, 15:29:36 UTC
Previous filing: 19 Nov 2021
Next filing: 02 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+209	+0.95%		22,206	26 Jan 2022	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$898	-111	-0.5%	$8.09	22,095	26 Jan 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-209	-100%	$0.000000^*	0	26 Jan 2022	Ordinary Shares	209		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3	The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.